The overall purpose of this study is to learn more about the metabolic effects of
angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic
approaches to increase angiotensin-(1-7) levels or its actions are currently in development
for treatment of metabolic-related diseases such as obesity and type II diabetes, based on
findings from animal studies. It is unclear if this peptide contributes to the regulation of
metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve
insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with
obesity and insulin resistance. The investigators will also examine for changes in blood
pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University
Treatments:
Angiotensin I (1-7) Angiotensin II Angiotensinogen